Atara Biotherapeutics, Inc.
ATRA
$7.94
-$0.08-1.00%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 258.77% | 670.30% | 1,779.79% | 2,892.69% | 2,131.40% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 258.77% | 670.30% | 1,779.79% | 2,892.69% | 2,131.40% |
| Cost of Revenue | -10.37% | -24.66% | -13.41% | -36.30% | -29.30% |
| Gross Profit | 450.22% | 93.56% | 80.24% | 84.57% | 72.62% |
| SG&A Expenses | 2.61% | -9.13% | -14.91% | -33.17% | -29.44% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.02% | -21.86% | -13.66% | -35.73% | -29.33% |
| Operating Income | 283.48% | 77.10% | 68.75% | 74.97% | 64.66% |
| Income Before Tax | 219.80% | 78.97% | 68.59% | 73.21% | 57.55% |
| Income Tax Expenses | -- | -272.73% | 10.53% | -- | 9.09% |
| Earnings from Continuing Operations | 219.71% | 79.00% | 68.61% | 73.21% | 57.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 219.71% | 79.00% | 68.61% | 73.21% | 57.53% |
| EBIT | 283.48% | 77.10% | 68.75% | 74.97% | 64.66% |
| EBITDA | 300.80% | 78.68% | 69.99% | 76.44% | 65.96% |
| EPS Basic | 162.53% | 91.52% | 82.11% | 81.67% | 68.59% |
| Normalized Basic EPS | 192.61% | 90.45% | 82.10% | 82.01% | 73.29% |
| EPS Diluted | 161.95% | 91.52% | 82.11% | 81.67% | 68.57% |
| Normalized Diluted EPS | 191.86% | 90.45% | 82.10% | 82.01% | 73.29% |
| Average Basic Shares Outstanding | 91.43% | 147.61% | 75.42% | 46.12% | 35.21% |
| Average Diluted Shares Outstanding | 92.98% | 147.61% | 75.42% | 46.12% | 35.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |